quotient sciences clinical content

  1. Accelerate Development Of Enabled Formulations For Poorly Soluble Drugs 8/21/2023

    Explore how a platform integrating drug substance, drug product, and clinical testing within a single organization accelerates development and reduces costs, helping deliver positive outcomes earlier.

  2. A Smarter Strategy For Optimizing Oncology Drug Products 7/14/2023

    John McDermott, VP of Scientific Consulting, shares insights on the benefits of evaluating targeted oncology molecules in healthy volunteers and applying an effective platform to accelerate drug product optimization.

  3. Strategies For Achieving Regulatory Milestones Faster 6/20/2023

    Explore how a vendor that offers integrated drug substance, drug product, and clinical testing activities under one organization facilitates improved communication and a more agile approach to development.

  4. Non-Clinical vs Clinical: Risks & Considerations When Developing Modified Release Dosage Forms 2/8/2023

    Explore case studies to describe the specialized formulation technologies that are available in the “toolbox” to achieve an optimal target product profile.

  5. A Streamlined Approach To 14C Human ADME Studies 2/8/2023

    Understand the benefits of a program that allows for a flexible approach to human ADME studies and the breadth of supporting data and case studies that demonstrate both significant time and cost savings.

  6. Integrated Programs To Bridge Molecules From Discovery Into Clinical Development 1/4/2023

    A new collaboration helps to remove obstacles from the critical path, reduce development risks, eliminate the white space in pre-clinical drug development, and shorten the pathway to clinical development.

  7. Spotlight On Clinical Operations 10/26/2022

    The role of clinical operations plays an important part in the overall drug development process. Ian Nisbet, Global Vice President of Clinical Operations at Quotient Sciences, shares more about clinical operations.

  8. Overcoming Small Molecule Challenges In Early Drug Development 7/19/2022

    Chris Roe, principal research fellow at Quotient Sciences, discusses effective strategies to overcome biopharmaceutic challenges for small molecules in today’s drug development pipeline.

  9. Streamlined Strategies To First-In-Human & Beyond 7/19/2022

    Dr. Stephen McQuaker explores case studies to demonstrate how drug substance and drug product development plans can be accelerated through innovative science and expertise to get drug substance off the critical path.

  10. Once Your Drug Substance Has Been Manufactured, How Do You Successfully Bridge Into Drug Product Development? 6/8/2022

    After your drug substance has been manufactured, the next challenge is formulating your API with other inactive ingredients (excipients) into a finished dosage form (drug product) for clinical trials.